New therapeutic cannabidiol derivatives

Summary of the technology

New therapeutic cannabidiol derivatives
CSIC, Temple University, and the University of North Carolina Greensboro have developed pyrazolylbenzene-1,3-diols for diseases associated with G protein-coupled receptor 18 (GPR18) and in combination with transient receptor potential vanilloid 1 (TRPV1) potentially useful against a wide range of disorders.
Industrial partners from the biotech or pharmaceutical industry are being sought to collaborate through joint development and patent license agreement.
An offer for Patent Licensing

CSIC - Consejo Superior de Investigaciones Científicas

New set of active molecules

Scaffold modulating the activity of GPR18 The invention relates to new cannabidiol derivatives useful for therapy and/or prophylaxis related to GPR18 and TRPV1 associated deseases. The compounds preferentially modulate the activity of GPR18 or have dual activity on GPR18 and TPRV1.
GPR18 is a G Protein-coupled receptor related to the endocannabinoid system. Its expression distribution pattern suggests a potential role of GPR18 in the immune system activity, in particular in microglial migration, pro-inflammation and cytotoxicity implicated in several neurodegenerative diseases, including multiple sclerosis and Alzheimer's disease. GPR18 has also been proposed as novel therapeutic target for metabolic disorders such as obesity and diabetes, glaucoma disease, cardiac function improvement, and neuropathic pain.
The transient receptor potential vanilloid 1(TRPV1) is a cation channel with high permeability for Ca 2+ . TRPV1 is involved in sensory and pain perception. It also plays a role in diabetes mellitus type-2 disorders, and neurological and psychiatric disorders such as epilepsy, anxiety, depression, and drug-addiction disorders.

Main innovations and advantages

· GPR18 receptor is involved in the immune system, infections leading to acute inflammation process, metabolic disorders and organ protection, including protection against neurodegenerative diseases and cancer protection

· Activation of GPR18 lowers intraocular pressure and improves cardiac function.

· TRPV1 is a receptor involved in sensory and pain perception, and plays a role in diabetes

· T-2 and psychiatric and neurological disorders.

· This new set of cannabidiol derivatives are more potent than natural or endogenous cannabinoids

Intellectual property status

  • Granted Patent
  • Patent application number :-

Related Keywords

  • Pharmaceutical Products / Drugs
  • Medical Health related
  • immune system
  • derivatives

About CSIC - Consejo Superior de Investigaciones Científicas

The Spanish National Research Council (in Spanish 'Consejo Superior de Investigaciones Científicas (CSIC)') is a government agency for basic and applied scientific research.

It is the largest public research organization in Spain, with presence in all the Autonomous Communities through 126 centers and 145 associated units.

CSIC - Consejo Superior de Investigaciones Científicas

Never miss an update from CSIC - Consejo Superior de Investigaciones Científicas

Create your free account to connect with CSIC - Consejo Superior de Investigaciones Científicas and thousands of other innovative organizations and professionals worldwide

CSIC - Consejo Superior de Investigaciones Científicas

Send a request for information
to CSIC - Consejo Superior de Investigaciones Científicas

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support